NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

OV Evgenov, P Pacher, PM Schmidt, G Haskó… - Nature reviews Drug …, 2006 - nature.com
Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric
oxide (NO). Impaired bioavailability and/or responsiveness to endogenous NO has been …

NO‐and haem‐independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle

JP Stasch, P Schmidt, C Alonso‐Alija… - British journal of …, 2002 - Wiley Online Library
Soluble guanylyl cyclase (sGC) is the only proven receptor for the ubiquitous biological
messenger nitric oxide (NO) and is intimately involved in many signal transduction …

NO-independent, haem-dependent soluble guanylate cyclase stimulators

JP Stasch, AJ Hobbs - cGMP: Generators, Effectors and Therapeutic …, 2009 - Springer
The nitric oxide (NO) signalling pathway is altered in cardiovascular diseases, including
systemic and pulmonary hypertension, stroke, and atherosclerosis. The vasodilatory …

[HTML][HTML] From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators

P Sandner - Biological chemistry, 2018 - degruyter.com
Nitric oxide (NO) signaling represents one of the major regulatory pathways for
cardiovascular function. After the discovery of NO, awarded with the Nobel Prize in 1998 …

Stimulators and activators of soluble guanylate cyclase: review and potential therapeutic indications

B Nossaman, E Pankey… - Critical care research and …, 2012 - Wiley Online Library
The heme‐protein soluble guanylyl cyclase (sGC) is the intracellular receptor for nitric oxide
(NO). sGC is a heterodimeric enzyme with α and β subunits and contains a heme moiety …

[HTML][HTML] Soluble guanylate cyclase stimulators and activators

P Sandner, DP Zimmer, GT Milne, M Follmann… - Reactive oxygen …, 2021 - Springer
Abstract When Furchgott, Murad, and Ignarro were honored with the Nobel prize for the
identification of nitric oxide (NO) in 1998, the therapeutic implications of this discovery could …

The chemistry and biology of soluble guanylate cyclase stimulators and activators

M Follmann, N Griebenow, MG Hahn… - Angewandte Chemie …, 2013 - Wiley Online Library
The vasodilatory properties of nitric oxide (NO) have been utilized in pharmacotherapy for
more than 130 years. Still today, NO‐donor drugs are important in the management of …

NO-and haem-independent soluble guanylate cyclase activators

HHHW Schmidt, PM Schmidt, JP Stasch - cGMP: Generators, Effectors and …, 2009 - Springer
Oxidative stress, a risk factor for several cardiovascular disorders, interferes with the
NO/sGC/cGMP signalling pathway through scavenging of NO and formation of the strong …

Regulation of nitric oxide-sensitive guanylyl cyclase

A Friebe, D Koesling - Circulation research, 2003 - Am Heart Assoc
In this review, we outline the current knowledge on the regulation of nitric oxide (NO)-
sensitive guanylyl cyclase (GC). Besides NO, the physiological activator that binds to the …

Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease

JP Stasch, P Pacher, OV Evgenov - Circulation, 2011 - Am Heart Assoc
Soluble guanylate cyclase (sGC), a key enzyme of the nitric oxide (NO) signaling pathway, is
attracting rapidly growing interest as a therapeutic target in cardiopulmonary disease, with …